Wu Hongqin, Ruan Xiangyan, Jin Jing, Mueck Alfred Otto
a Department of Gynecological Endocrinology , Beijing Obstetrics & Gynecology Hospital, Capital Medical University , Chaoyang District , Beijing , China and.
Gynecol Endocrinol. 2015 Jul;31(7):548-51. doi: 10.3109/09513590.2015.1029447. Epub 2015 May 25.
The aim of this study was to compare the effect of Diane-35 versus Diane-35 + metformin on metabolic parameters in Chinese PCOS patients.
Patients getting individualized life-style modification were treated with Diane-35. Metformin was added according to its indication. Within a 3-month prospective study, metabolic parameters were assessed.
Eighty-three patients were recruited, 45 using Diane-35 and 38 Diane-35 plus metformin. Using Diane-35, triglycerides (TG) (p < 0.05) and tendencially (p < 0.1) total cholesterol (TC) increased, but significant positive effects on BMI, high-density lipoprotein cholesterol (HDL-C), and HDL-C/TC ratio were observed. Other lipids and the parameters for glucose metabolism remained unchanged. In the combination group, no negative effect on TG and TC was seen, other lipid fractions improved, as well as BMI, % body fat, and all parameters for glucose metabolism like fasting plasma glucose (FPG), fasting insulin, HOMA-insulin-resistance index, and insulin sensitivity index (ISI), whereby the beneficial effect of metformin got significance compared with Diane-35 for BMI, FPG, and ISI.
With the exception of increasing triglycerides, Diane-35 had no relevant negative effects in the metabolic system. It does not negatively impact the beneficial effects of metformin in lipids and glucose metabolism. Diane-35 plus metformin is effective in improving the metabolic profile of Chinese PCOS patients.
本研究旨在比较达英-35与达英-35联合二甲双胍对中国多囊卵巢综合征(PCOS)患者代谢参数的影响。
接受个体化生活方式调整的患者接受达英-35治疗。根据适应证加用二甲双胍。在一项为期3个月的前瞻性研究中,评估代谢参数。
共招募83例患者,45例使用达英-35,38例使用达英-35加二甲双胍。使用达英-35时,甘油三酯(TG)(p<0.05)及总胆固醇(TC)呈趋势性升高(p<0.1),但对体重指数(BMI)、高密度脂蛋白胆固醇(HDL-C)及HDL-C/TC比值有显著的积极影响。其他血脂及糖代谢参数未改变。在联合治疗组中,未观察到对TG和TC的负面影响,其他血脂成分得到改善,BMI、体脂百分比以及所有糖代谢参数如空腹血糖(FPG)、空腹胰岛素、稳态模型胰岛素抵抗指数和胰岛素敏感指数(ISI)均得到改善,其中二甲双胍在BMI、FPG和ISI方面的有益作用与达英-35相比具有显著性。
除甘油三酯升高外,达英-35对代谢系统无相关负面影响。它不会对二甲双胍在脂质和糖代谢方面的有益作用产生负面影响。达英-35联合二甲双胍可有效改善中国PCOS患者的代谢状况。